Form 8K MaxCyte Inc For: 12 January
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MaxCyte Inc (MXCT)
Assess today's live MaxCyte Inc (MXCT) share price, performance and insights using our live NASDAQ: MXCT stock exchange data.
Analyse the historical data and MaxCyte Inc share price performance charts on this page. Our technical summary section provides analysis on MaxCyte share price buy/sell indicators using real-time data (or discuss the MaxCyte (MXCT) stock price today with other investors in the MaxCyte NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ MXCT share price (ISIN: US57777K1060) to enhance your trading decisions with our free investment tools and resources.
What Is the MaxCyte Inc Share Price Today?
The MaxCyte share price today is 1.160.
What Is the Stock Symbol for MaxCyte Inc
The stock symbol (or 'ticker') for MaxCyte Inc is "MXCT."
What Stock Exchange Does MaxCyte Inc Trade On?
MaxCyte Inc is listed and trades on the NASDAQ stock exchange.
Is MaxCyte Inc a Good Stock to Buy?
Determining whether MaxCyte Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and MaxCyte Inc share price performance charts on this page. Our technical summary section provides analysis on MaxCyte share price buy/sell indicators using real-time data (or discuss the MaxCyte (MXCT) stock price today with other investors in the MaxCyte NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ MXCT share price (ISIN: US57777K1060) to enhance your trading decisions with our free investment tools and resources.
What Is the MaxCyte Inc Share Price Today?
The MaxCyte share price today is 1.160.
What Is the Stock Symbol for MaxCyte Inc
The stock symbol (or 'ticker') for MaxCyte Inc is "MXCT."
What Stock Exchange Does MaxCyte Inc Trade On?
MaxCyte Inc is listed and trades on the NASDAQ stock exchange.
Is MaxCyte Inc a Good Stock to Buy?
Determining whether MaxCyte Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.140
1.260
52 wk Range
1.140
4.900
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.1401.260
52 wk Range
1.1404.900
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MXCT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
7.240
Upside
+524.14%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 13G MAXCYTE For: 14 November
- Investing.com
- Form 8K MaxCyte Inc For: 12 January
- Investing.com
- Form 13G MAXCYTE For: 14 November
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
MaxCyte Company Profile
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte Inc Earnings Call Summary for Q2/2025
- MaxCyte Q2 revenue missed forecast at $8.5M, EPS at -$0.12; stock dipped 0.97% to $2.04, near 52-week low
- 2025 core revenue guidance lowered to flat or down 10%; company projects $155M cash by year-end
- Strong cash position of $165.2M with no debt; gross margin declined to 82% from 86% year-over-year
- Focus on operational efficiency and Asia Pacific growth; new platform launch planned for late 2025
- CEO remains optimistic about MaxCyte's position in cell and gene therapy market despite short-term challenges
Last Updated: 07/08/2025, 08:36
Read Full TranscriptCompare MXCT to Peers and Sector
Metrics to compare | MXCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMXCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.7x | −1.0x | −0.6x | |
PEG Ratio | 0.11 | −0.04 | 0.00 | |
Price/Book | 0.7x | 3.2x | 2.6x | |
Price / LTM Sales | 3.6x | 2.9x | 3.4x | |
Upside (Analyst Target) | - | 78.6% | 41.5% | |
Fair Value Upside | Unlock | 10.5% | 4.4% | Unlock |
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 7.240
(+524.14% Upside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
-0.12 / -0.1133
Revenue / Forecast
6.83M / 8.63M
People Also Watch
FAQ
What Is the MaxCyte (MXCT) Share Price Today?
The live MaxCyte share price today is 1.160
What Stock Exchange Does MaxCyte (MXCT) Trade On?
MaxCyte is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for MaxCyte?
The stock symbol (also called a 'ticker') for MaxCyte is "MXCT."
What Is the Current MaxCyte Market Cap?
As of today, MaxCyte market capitalisation is 123.74M.
What Is MaxCyte's (MXCT) Earnings Per Share (TTM)?
The MaxCyte EPS is currently -0.43 (Trailing Twelve Months).
When Is the Next MaxCyte Earnings Date?
MaxCyte's next earnings report will be released on 17 Mar 2026.
Is MXCT a Buy or Sell From a Technical Analyst Perspective?
Based on today's MaxCyte moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has MaxCyte Stock Split?
MaxCyte has split 0 times. (See the MXCT stock split history page for full effective split date and price information.)
How Many Employees Does MaxCyte Have?
MaxCyte has 114 employees.
What is the current trading status of MaxCyte (MXCT)?
As of 25 Jan 2026, MaxCyte (MXCT) is trading at a price of 1.160, with a previous close of 1.250. The stock has fluctuated within a day range of 1.140 to 1.260, while its 52-week range spans from 1.140 to 4.900.
What Is MaxCyte (MXCT) Price Target According to Analysts?
The average 12-month price target for MaxCyte is USD7.240, with a high estimate of USD9 and a low estimate of USD5.72. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +524.14% Upside potential.
What Is the MXCT After Hours Price?
MXCT's last after hours stock price is 1.208, the stock has decreased by 0.048, or 4.130%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.